Trials / Unknown
UnknownNCT05174156
Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR-1210 in combination with paclitaxel and platinum in advanced esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combination therapy | SHR-1210 (camrelizumab) + albumin-bound paclitaxel + Carboplatin |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
- First posted
- 2021-12-30
- Last updated
- 2022-07-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05174156. Inclusion in this directory is not an endorsement.